Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126647271 | 12664727 | 1 | I | 20140101 | 20140312 | 20160818 | 20160818 | PER | CA-BAYER-2014-039138 | BAYER | 37.00 | YR | A | F | Y | 0.00000 | 20160818 | MD | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126647271 | 12664727 | 1 | PS | BETASERON | INTERFERON BETA-1B | 1 | 0.25 MG, UNK | Y | 31135A | 103471 | .25 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | ||||||
| 126647271 | 12664727 | 2 | SS | BETASERON | INTERFERON BETA-1B | 1 | 0.250 MG, UNK | Y | 41060A | 103471 | .25 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | ||||||
| 126647271 | 12664727 | 3 | C | CELEXA | CITALOPRAM HYDROBROMIDE | 1 | UNK | 0 | |||||||||||
| 126647271 | 12664727 | 4 | C | ZOPLICONE | ZOPICLONE | 1 | 7.5 MG, QD | 0 | 7.5 | MG | QD | ||||||||
| 126647271 | 12664727 | 5 | C | TRAZODONE | TRAZODONE HYDROCHLORIDE | 1 | 12.5 MG, UNK | 0 | 12.5 | MG | |||||||||
| 126647271 | 12664727 | 6 | C | VITAMIN D | CHOLECALCIFEROL | 1 | 4000 IU, UNK | 0 | 4000 | IU | |||||||||
| 126647271 | 12664727 | 7 | C | VITAMIN B COMPLEX | CYANOCOBALAMINDEXPANTHENOLNIACINAMIDEPYRIDOXINE HYDROCHLORIDERIBOFLAVIN 5'-PHOSPHATE SODIUMTHIAMINE HYDROCHLORIDEVITAMIN B COMPLEX | 1 | 1000 IU, UNK | 0 | 1000 | IU | |||||||||
| 126647271 | 12664727 | 8 | C | SILVER | SILVER | 1 | 0 | ||||||||||||
| 126647271 | 12664727 | 9 | C | CITICOLINE | CITICOLINE | 1 | 0 | ||||||||||||
| 126647271 | 12664727 | 10 | C | NALTREXONE | NALTREXONE | 1 | 0 | ||||||||||||
| 126647271 | 12664727 | 11 | C | CALCIUM [CALCIUM] | CALCIUM | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126647271 | 12664727 | 1 | Multiple sclerosis |
| 126647271 | 12664727 | 2 | Multiple sclerosis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126647271 | 12664727 | OT |
| 126647271 | 12664727 | DS |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126647271 | 12664727 | Anxiety | |
| 126647271 | 12664727 | Balance disorder | |
| 126647271 | 12664727 | Drug ineffective | |
| 126647271 | 12664727 | Injection site discolouration | |
| 126647271 | 12664727 | Injection site mass | |
| 126647271 | 12664727 | Injection site rash | |
| 126647271 | 12664727 | Limb discomfort | |
| 126647271 | 12664727 | Mobility decreased | |
| 126647271 | 12664727 | Multiple sclerosis | |
| 126647271 | 12664727 | Multiple sclerosis relapse | |
| 126647271 | 12664727 | Musculoskeletal discomfort | |
| 126647271 | 12664727 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126647271 | 12664727 | 1 | 20020101 | 20150115 | 0 | |
| 126647271 | 12664727 | 2 | 20150804 | 0 | ||
| 126647271 | 12664727 | 3 | 20150115 | 0 |